Co-administration of CD19 and CD22 CAR-T therapy in pediatric relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
Years Later, These Kids With Tough Leukemia Are Still in Remission
This retrospective subanalysis evaluated long-term outcomes in pediatric patients with relapsed/refractory Philadelphia chromosome-positive …
Pairing two reprogrammed immune cell therapies gave most kids with an aggressive form of leukemia long-term remission — without a single tre…
In children with Ph+ ALL, TKI-based therapy reduced HSCT use while maintaining comparable outcomes versus Ph+ALL04
Reduced transplant use showed similar outcomes in children with Philadelphia chromosome-positive leukemia
This single-arm Phase 2 trial evaluated chemotherapy with tyrosine kinase inhibitors (TKIs) guided by minimal residual disease in 41 eligibl…
Children with a specific leukemia type achieved similar survival rates without stem cell transplants, offering a less intensive treatment op…
Research across Cancer
Related studies from across the Cancer family.
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies
New Strategies Identified to Overcome CAR T-cell Therapy Resistance
This systematic review synthesizes current knowledge regarding resistance mechanisms and overcoming strategies for CAR T-cell therapy in rel…
Researchers identified specific ways to overcome resistance in CAR T-cell therapy for patients with certain types of blood cancers.
Fertility preservation in female leukemia patients carries risks of leukemic cell contamination and disease reintroduction
Fertility preservation options carry risks for female leukemia patients
This review examines fertility preservation strategies for female patients with leukemia. The authors note that oocyte or embryo cryopreserv…
Fertility preservation strategies for female leukemia patients face safety concerns like disease reintroduction and contamination risks that…
Review discusses pharmacogenomic biomarkers for pediatric B-ALL chemotherapy dosing
New review looks at using genetic tests to adjust cancer drug doses for kids
This narrative review examines the role of pharmacogenomic biomarkers and genotype-guided dose adjustments in pediatric B-cell acute lymphob…
A recent review suggests that checking specific genes before treatment can help doctors give the right amount of chemotherapy to children wi…
Review of a case of Down syndrome T-ALL with complex karyotype and treatment response
Boy with Down syndrome beats rare leukemia after tailored chemo
This narrative review and case report describes a 7-year-old boy with Down syndrome and T-cell acute lymphoblastic leukemia treated with AIE…
A 7-year-old with Down syndrome and a rare T-cell leukemia achieved remission after tailored chemotherapy, despite severe complications.
Combining pegylated interferon with nilotinib improves early molecular response in newly diagnosed chronic phase chronic myeloid leukaemia
Adding a weekly shot to a daily leukemia pill boosts deep remission rates
This phase 3 trial compared nilotinib monotherapy against nilotinib combined with pegylated interferon alfa-2a in patients with newly diagno…
A weekly injection added to a daily pill helped more newly diagnosed CML patients reach deep remission, but it also caused more side effects…
Systematic review and meta-analysis finds high prevalence of ocular manifestations in leukemia patients
Leukemia patients face eye risks that doctors must spot early now
This systematic review and meta-analysis of 1016 patients with leukemia found a 42% prevalence of overall ocular manifestations.
New data shows almost half of leukemia patients have eye issues, so regular eye checks are essential for better care
Meta-analysis links perinatal factors to childhood acute leukemia risk
Perinatal factors linked to higher leukemia risk in children
This systematic review and meta-analysis of 85 studies examined perinatal factors and childhood acute leukemia risk.
A large analysis of 85 studies finds links between birth weight, maternal history, and cesarean sections with childhood leukemia risk.
PD-L1-armored CAR-T followed by allo-HSCT yields 7-year remission in refractory B-cell ALL
New Leukemia Treatment Keeps Adult Patient Cancer Free For Seven Years
This retrospective observational analysis of a single clinical case describes an adult patient with early-relapsed, chemorefractory B-cell a…
A new dual-targeted therapy helped an adult with tough leukemia stay cancer-free for seven years after standard treatments failed.
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias
New T-Cells Fight Blood Cancer Without Matching Your DNA
This narrative review synthesizes evidence on gamma delta T cell therapies for acute leukemias, lymphomas, multiple myeloma, and immune cyto…
A new type of immune cell could finally treat blood cancers that other therapies cannot touch.
Meta-analysis links DNA repair gene polymorphisms to leukemia risk across 54 studies
DNA Repair Flaws May Raise Leukemia Risk
This meta-analysis of 54 studies examines associations between DNA repair gene polymorphisms and leukemia risk.
Imagine your cells have a built-in repair crew that fixes mistakes in your DNA every day.
Review compares 68Ga-pentixafor and 18F-FDG PET/CT in a single CLL patient
A New Scan Spots a Tricky Blood Cancer Far More Clearly
This case report and review of literature evaluates diagnostic performance of 68Ga-pentixafor versus 18F-FDG PET/CT in a 60-year-old woman w…
A new PET scan tracer spots chronic lymphocytic leukemia more clearly than standard imaging, helping doctors see disease extent in patients …
Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy
Two Rare Diseases Strike After Lung Cancer Treatment
This case report and literature review describes the management of a 54-year-old male with locally advanced lung squamous cell carcinoma, th…
A lung cancer patient treated with chemo and immunotherapy developed two rare diseases simultaneously: a new blood cancer and tuberculosis.